Doximity, Inc. (NYSE:DOCS – Get Free Report) Director Watkin Phoebe Yang sold 1,290 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $26.71, for a total transaction of $34,455.90. Following the completion of the sale, the director directly owned 24,744 shares in the company, valued at $660,912.24. This represents a 4.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Doximity Price Performance
DOCS stock traded down $0.55 during midday trading on Friday, reaching $27.95. The company had a trading volume of 2,672,127 shares, compared to its average volume of 4,021,538. Doximity, Inc. has a 1 year low of $17.15 and a 1 year high of $74.33. The company has a market capitalization of $4.98 billion, a P/E ratio of 32.89, a P/E/G ratio of 22.17 and a beta of 1.22. The firm has a 50-day moving average price of $25.04 and a 200-day moving average price of $23.23.
Doximity (NYSE:DOCS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. Doximity’s quarterly revenue was up 7.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.36 EPS. On average, equities analysts predict that Doximity, Inc. will post 0.74 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. Bank of America restated an “underperform” rating and set a $20.00 price target (down from $38.00) on shares of Doximity in a research report on Monday, June 29th. Wolfe Research upgraded Doximity to an “outperform” rating in a research report on Thursday, August 13th. Zacks Research raised Doximity from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wells Fargo & Company downgraded Doximity from an “equal weight” rating to an “underweight” rating and set a $18.00 target price for the company. in a research report on Monday, August 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $47.00 target price (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, fourteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $31.95.
Doximity Company Profile
Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.
The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.
Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.
Further Reading
- Five stocks we like better than Doximity
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
